Nanomerics today announced publication of a scientific paper which helps to elucidate the some of the mechanisms involved in the efficient oral peptide delivery seen with its MET system.
"By encapsulating the gut labile peptides in the MET nanoparticles we prevent their degradation in the gut. This then allows them to be taken up by the enterocytes (cells lining the gut) and subsequently transported into the blood." explains Prof Ijeoma Uchegbu, CSO of Nanomerics and one of the authors of the study.
Nanomerics CEO, Andreas Schatzlein emphasises:"This findings are very significant as they allow us to understand and optimise the performance of nanomedicines such as Nanomerics' MET system. These types of therapies promise to open up the use of peptides, molecules made by our bodies as nature's own drugs, as in therapies for the treatment of many important diseases such as diabetes and cancer."